临床与实验病理学杂志2017，Vol.33Issue(11)：1183-1187,5.DOI:10.13315/j.cnki.cjcep.2017.11.002
非小细胞肺癌患者肿瘤组织多驱动基因联合检测及其临床意义
Driver gene mutations among non-small cell lung cancer tissues and its clinical significance
摘要
Abstract
Purpose To investigate the mutation rate of EGFR,KRAS,ALK and ROS1 in non-small cell lung cancer (NSCLC) and its association with clinical or pathological characteristics.Methods 86 NSCLC tissues were included.Fluorescence PCR was used to detect the EGFR,KRAS mutation and ALK,ROS1 fusion gene.The association between EGFR,KRAS,ALK and ROS1 gene and age,gender,smoking history,histological type,lymph node metastasis and other clinical pathological features were analyzed.Results The total mutation rate of the driver gene in NSCLC patients was 62.8％ (54/86).EGFR mutation rate was 76％ (41/54).KRAS mutation rate was 9.3％ (5/54).ALK gene fusion mutation rate was 13.0％ (7/54),and in one of the patients,EGFR 19 deletion mutation and ALK fusion co-exist.ROS1 gene fusion mutation was 3.8％ (2/54).EGFR gene mutation rate was higher in adenocarcinoma and female (P ＜ 0.05),but no significant association was found in age,smoking history and lymph node metastasis (P ＞0.05).KRAS,ALK,ROS1 genes had no obvious correlation with clinical pathological features (P ＞ 0.05).Conclusion The EGFR mutation and ALK fusion was rather high in patients with NSCLC.More attention should be paid to them.Though KRAS,ROS1 mutations and double mutations were low in NSCLC patients,they should not be ignored.关键词
肺肿瘤/非小细胞肺癌/表皮生长因子受体/KRAS/ALK/ROS1Key words
lung neoplasm/non-small cell lung cancer/EGFR/KRAS/ALK/ROS1分类
医药卫生引用本文复制引用
杨长绍,杨延龙,丁晓洁,杜亚茜,李权,郭银金,刘俊熙,周永春..非小细胞肺癌患者肿瘤组织多驱动基因联合检测及其临床意义[J].临床与实验病理学杂志,2017,33(11):1183-1187,5.基金项目
国家自然科学基金(81460441)、云南省应用基础研究面上项目(2016FB145)、云南省卫生科技计划(2014NS001) （81460441）
